换股比率为1股H股可换取0.263614股要约人H股，即要约人将发行0.263614股要约人H股以换取1股H 股。 东阳光（600673）长江药业(01558)及要约人广东东阳光药业股份有限公司联合公布，联交所已经批准 撤销H股在联交所的上市地位，于2025年8月5日下午4时正起生效。 ...

Core Viewpoint - Dongyangguang Changjiang Pharmaceutical (01558) and the offeror Guangdong Dongyangguang Pharmaceutical Co., Ltd. jointly announced the approval of the delisting of H-shares from the Stock Exchange, effective from August 5, 2025, at 4:00 PM [1] Summary by Relevant Sections - Delisting Approval - The Stock Exchange has approved the delisting of H-shares for Dongyangguang Changjiang Pharmaceutical, which will take effect on August 5, 2025 [1] - Exchange Ratio - The exchange ratio is set at 1 H-share for 0.263614 shares of the offeror's H-shares, meaning the offeror will issue 0.263614 shares for each H-share exchanged [1]

Core Viewpoint - Dongyangguang Pharmaceutical is integrating its R&D capabilities with its nationwide sales network to accelerate global operations and drive value reconstruction after its listing on the Hong Kong Stock Exchange on August 7 [1] Group 1: Business Integration and Market Position - The company aims to establish a closed-loop system of R&D, production, and sales, which is crucial for its core value reassessment [1] - The integration is expected to enhance the commercial value of its product pipeline, contributing to a solid foundation for Dongyangguang Pharmaceutical [1] Group 2: Product Pipeline and Revenue Potential - Dongyangguang Pharmaceutical has a rich pipeline of high-potential innovative drugs, with 3 original innovative drugs already launched and 49 in the research phase, including 1 nearing market approval and 10 in clinical phases II and III [2] - The company’s product, Ifenprodil, is the first domestic drug entering phase III clinical trials for IPF treatment, with potential for expansion into PF-ILD and liver fibrosis, positioning it as a best-in-class product in the global fibrosis market [2] - The application for the U.S. market for Glargine insulin injection has been submitted, potentially making Dongyangguang Pharmaceutical the first Chinese company to bypass phase III trials for this drug in the U.S. [2] - The U.S. insulin market exceeds $10 billion, and successful approvals for Dongyangguang Pharmaceutical's insulin products could significantly boost its overseas revenue [2] - The company has several overseas business development projects, many with authorization values exceeding $1 billion, indicating substantial commercial value release potential [2] Group 3: Strategic Outlook - With the listing on August 7, Dongyangguang Pharmaceutical's innovative drug assets are expected to leverage the integrated R&D-production-sales model and the rapid development of the innovative drug industry to quickly ascend to the ranks of leading innovative drug developers [2]

Core Viewpoint - Dongyangguang Pharmaceutical is set to debut on the Hong Kong Stock Exchange as the first H-share absorption merger and introduction listing case, marking a significant milestone in the company's 20-year journey in innovative drug development and a crucial step for domestic innovative pharmaceutical companies in asset securitization and internationalization [1][2]. Group 1: Company Background and Innovation - Founded in 2003 by Zhang Zhongneng, Dongyangguang Pharmaceutical has maintained a core focus on independent innovation since its inception, establishing a research institute in 2005 [2]. - The company has developed its first innovative drug, a treatment for chronic hepatitis C, which was approved for market in 2020, showcasing its commitment to overcoming significant challenges in drug development [2]. - Dongyangguang Pharmaceutical has accumulated a robust pipeline of 49 innovative drugs in development, with 3 already approved and 10 in clinical phases II and III, indicating strong potential for future growth [3][4]. Group 2: Research and Development Capabilities - The company has established a diverse research and development platform, covering various drug types and advanced technologies, including small molecules, small nucleic acids, and CAR-T therapies [3][4]. - Dongyangguang Pharmaceutical has over 2,500 invention patents and has received numerous awards, including the National Key Laboratory for Anti-Infective Drug Research, highlighting its strong innovation credentials [5]. Group 3: Internationalization Strategy - The company is accelerating its internationalization strategy, having established a comprehensive R&D, production, registration, and commercialization capability, with a focus on both domestic and international markets [6][7]. - Dongyangguang Pharmaceutical has received regulatory approvals for 68 drugs in Europe and the U.S., positioning it among the leading Chinese pharmaceutical companies in terms of approval numbers [7]. - The company has signed a licensing agreement with UK-based Apollo for the exclusive development and commercialization rights of its innovative drug HEC88473 outside Greater China, with a transaction value nearing $1 billion [7]. Group 4: Future Outlook - The listing on the Hong Kong Stock Exchange is seen as a new starting point for Dongyangguang Pharmaceutical, which aims to leverage international capital markets to further its global reach and enhance its competitive edge [8][10]. - The company is committed to continuing its dual strategy of innovation and internationalization, with plans to accelerate the commercialization of its innovative drugs and expand its global footprint [9][10].

Core Viewpoint - Dongyangguang Pharmaceutical is set to debut on the Hong Kong Stock Exchange on August 7, marking a significant milestone in its 20-year journey of innovation in the pharmaceutical industry, and highlighting the progress of domestic innovative drug companies in asset securitization and internationalization [1] Innovation Leadership - The company has established a strong foundation for its listing through two decades of commitment to independent innovation, starting with its founding mission in 2003 [1][2] - Dongyangguang's first innovative drug, approved in 2020, exemplifies its pioneering spirit and has laid the groundwork for future product launches [2] - The company has a robust pipeline with 49 innovative drugs in development, including 10 in clinical phases II and III, showcasing its potential for significant market impact [3] - Dongyangguang has developed a diverse technical platform, integrating various drug types and advanced technologies, which supports rapid results transformation [3] - The company has accumulated over 2,500 patents and received numerous awards, reinforcing its core assets as it enters the capital market [4] Global Expansion - Chinese pharmaceutical companies are increasingly expanding internationally, with a notable rise in transaction volumes between multinational and domestic firms [5] - Dongyangguang has established a comprehensive international ecosystem, including a specialized overseas registration and intellectual property team [5] - The company has received multiple approvals for its drugs in Europe and the U.S., positioning itself as a leader among Chinese pharmaceutical firms [6] - Strategic partnerships, such as the licensing agreement with Apollo, highlight Dongyangguang's dual approach to internationalization through both internal development and external collaborations [6] Integrated Operations - The merger with Dongyangguang Changjiang Pharmaceutical will enhance the company's research, production, and commercialization capabilities, creating a closed-loop system for global operations [8] - The company aims to leverage its integrated platform to accelerate the market entry of innovative drugs and expand its international footprint [8] - Dongyangguang's commitment to high-tech and research innovation is expected to yield significant returns for both patients and investors [8][9]

智通财经APP讯，胜利股份(000407.SZ)公告，公司股东阳光人寿保险股份有限公司(简称"阳光人寿")因 自身经营需要计划自本公告披露之日起15个交易日后的3个月时间内，以集中竞价或大宗交易方式减持 公司股份不超过440万股(不超过公司总股本的0.50%)。 ...

胜利股份公告称，持股5%以上股东阳光人寿保险计划自公告披露之日起15个交易日后的3个月时间内， 以集中竞价或大宗交易方式减持公司股份不超过4,400,000股，不超过公司总股本的0.50%。减持价格不 低于2.8元/股，减持金额约为1,200万元-1,700万元。减持计划实施不会导致公司控制权发生变更，不会 对公司治理结构及持续经营产生影响。 ...

胜利股份公告，持股5%以上股东阳光人寿因自身经营需要，拟减持股份数量不超过440万股，不超过公 司总股本的0.50%。拟减持期间为自本公告披露之日起15个交易日后的3个月时间内。本次计划减持价 格不低于2.8元/股，减持金额约为1200万元-1700万元。 （文章来源：第一财经） ...

人民财讯8月4日电，胜利股份（000407）8月4日晚间公告，股东阳光（600673）人寿保险股份有限公司 (以下简称"阳光人寿")拟以集中竞价或大宗交易方式减持公司股份不超过440万股(不超过公司总股本的 0.5%)。 ...

Core Viewpoint - Dongyang Sunshine Pharmaceutical (06887) is set to list on the Hong Kong Stock Exchange on August 7, aiming to integrate its R&D capabilities with Dongyang Sunshine Changjiang Pharmaceutical's national sales network, creating a closed loop of R&D, production, and sales to accelerate global operations and drive value reconstruction [1][2]. Group 1: Market Expectations and Valuation - The market anticipates that Dongyang Sunshine Pharmaceutical's valuation post-listing could exceed HKD 50 billion, driven by the integration of its innovative drug assets and the overall revaluation of the innovative drug sector this year [1][2]. - The innovative drug sector has seen a significant revaluation and value release, reflecting heightened market confidence and attention, with Dongyang Sunshine Pharmaceutical's integrated model forming a crucial basis for its core value reassessment [1][2]. Group 2: Product Pipeline and Commercial Potential - Dongyang Sunshine Pharmaceutical boasts a robust pipeline of high-potential innovative drugs, with three original innovative drugs already launched and 49 in development, including one nearing market entry and ten in clinical phases II and III [2]. - Key products include Ifenprodil, the first domestic drug in III clinical trials for IPF, and insulin products with significant market potential in the U.S., where the insulin market exceeds USD 10 billion [2]. - The company has several projects with potential authorization values exceeding USD 1 billion, indicating substantial commercial value release from its expanding product pipeline [2].